AFT Pharmaceuticals (AFT Pharmaceuticals) Price-to-Owner-Earnings : (As of Jun. 23, 2024)

View and export this data going back to 2022. Start your Free Trial

What is AFT Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-06-23), AFT Pharmaceuticals's share price is $0.00. AFT Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for AFT Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

AFTPF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.71 Med: 46.43 Max: 96.27
Current: 30.68

During the past 9 years, the highest Price-to-Owner-Earnings of AFT Pharmaceuticals was 96.27. The lowest was 20.71. And the median was 46.43.

AFTPF's Price-to-Owner-Earnings is ranked worse than
59.62% of 426 companies
in the Drug Manufacturers industry
Industry Median: 24.595 vs AFTPF: 30.68

As of today (2024-06-23), AFT Pharmaceuticals's share price is $0.00. AFT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, AFT Pharmaceuticals's PE Ratio for today is N/A.

As of today (2024-06-23), AFT Pharmaceuticals's share price is $0.00. AFT Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, AFT Pharmaceuticals's PE Ratio without NRI for today is N/A.

During the past 9 years, AFT Pharmaceuticals's highest PE Ratio without NRI was 65.47. The lowest was 16.89. And the median was 34.90.

AFT Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for AFT Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Price-to-Owner-Earnings Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Price-to-Owner-Earnings

Get a 7-Day Free Trial

AFT Pharmaceuticals Quarterly Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Price-to-Owner-Earnings	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of AFT Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Price-to-Owner-Earnings falls into.

AFT Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

AFT Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	0.00	/	0.00
	=

AFT Pharmaceuticals (OTCPK:AFTPF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

AFT Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (AFT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (OTCPK:AFTPF) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.